Introduction
============

Glaucoma includes a diverse family of related, progressive, and irreversible optic neuropathies. Untreated glaucoma may progressively lead to retinal ganglion cell death, optic nerve damage, and vision loss. Several studies have shown that elevated intraocular pressure (IOP) is a major risk factor for the development of primary open-angle glaucoma.[@b1-opth-7-357]--[@b4-opth-7-357] Further, elevated IOP is the only risk factor amenable to treatment; the use of topical ocular hypotensive medications to reduce IOP has been effective in delaying or preventing disease progression and is therefore the mainstay of glaucoma treatment.[@b5-opth-7-357] Major classes of medications for IOP reduction include the beta-blockers (eg, timolol), alpha-adrenergic agonists (eg, brimonidine), carbonic anhydrase inhibitors (eg, brinzolamide or dorzolamide), and prostaglandin analogs (eg, travoprost).[@b6-opth-7-357]

While monotherapy with a single class of medication may be effective in lowering IOP, many patients require more than one medication for the adequate, long-term control of IOP.[@b5-opth-7-357] Therefore, in clinical practice, a two-drug regimen, consisting of a topical beta-blocker in combination with a carbonic anhydrase inhibitor or prostaglandin analog, is commonly administered to patients with insufficient IOP control with monotherapy. Fixed combinations of a beta-blocker and a carbonic anhydrase inhibitor that are currently available include brinzolamide 1%/timolol 0.5% (Azarga^®^; Alcon Inc, Fort Worth, TX, USA) and dorzolamide 2%/timolol 0.5% (Cosopt^®^; Merck and Co, Inc, Whitehouse Station, NJ, USA). In a previous clinical study, the IOP-lowering efficacy of brinzolamide/timolol was noninferior to dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension.[@b7-opth-7-357]

While the IOP-lowering efficacy of any glaucoma therapy is critical, selection of a suitable topical ocular medication for glaucoma also depends on other factors that may influence patient adherence to therapy, such as drop comfort upon instillation and overall tolerability.[@b8-opth-7-357] Therefore, the objective of this crossover study was to assess ocular discomfort upon instillation and patient preference for brinzolamide/timolol relative to dorzolamide/timolol, in patients with open-angle glaucoma or ocular hypertension.

Methods
=======

Study design
------------

This was a multicenter, prospective, patient-masked, randomized, interventional, crossover 3-day study. At screening (day 0), patients were assessed for study eligibility. Demographic information, medical histories, and information regarding contact lens wear (if applicable) were collected. A urine pregnancy test was conducted for women of childbearing potential. Additional assessments included best-corrected visual acuity (BCVA), a slit-lamp examination, and IOP measured bilaterally with Goldmann applanation tonometry. On day 0, patients were randomly assigned by eye (left or right) in a 1:1 ratio to receive one drop of brinzolamide 1%/timolol 0.5% (Azarga) in one eye and one drop of dorzolamide 2%/timolol 0.5% (Cosopt) in the contralateral eye, followed by day one treatment including one drop of either brinzolamide/timolol or dorzolamide/timolol, bilaterally. On day 2, patients received one drop of the alternate treatment assigned at day 1, bilaterally. Patients were unaware of their assigned treatment throughout the study.

Patients
--------

Eligible patients included men and women of any race or ethnicity who were 18 years of age or older and diagnosed with glaucoma (primary open-angle or pigment dispersion) or ocular hypertension in both eyes. Patients must have been on a stable IOP-lowering regimen for at least 30 days before screening. Specifically, patients must have been using any form of monotherapy for glaucoma (ie, any single therapeutic agent in a bottle) with the exception of a topical carbonic anhydrase inhibitor, which must not have been used (as a monotherapy or in a fixed combination product) within a year of study screening. Patients were not eligible if they had ocular conditions that could have prevented the safe administration of study medications or could have interfered with planned study assessments. Patients were not eligible if they had histories of ocular surgery, inflammatory eye disease, corneal dystrophies, opacities, and ocular infections; or signs and symptoms that were associated with these or other ocular conditions.

Upon entry and prior to participating in any study-related assessments, all potential patients provided their written informed consent. An independent ethics committee in each country approved the protocol, the participating investigator, and the informed consent document. The study was conducted in accordance with Good Clinical Practices and the ethical principles described within the Declaration of Helsinki; this study was registered at ClinicalTrials.gov as NCT01471158.

Assessments
-----------

### Assessment of ocular discomfort and patient preference

On both days 1 and day 2, within 1 minute following drop instillation, the patients rated their level of ocular discomfort with the study drug, using a 10-point Ocular Discomfort Scale (ODS). The ODS specifically ranged in whole-unit increments from 0 (no discomfort) to 9 (substantial discomfort). Separately, on day 2, after assessing their ocular discomfort, patients completed the patient preference question, reporting that they either preferred the first medication (instilled on day 1) or the second medication (instilled on day 2).

### Safety

Safety parameters included adverse events (AEs), evaluations of ocular signs (cornea, lens, eyelids/conjunctiva, and iris/anterior chamber) as assessed through slit-lamp biomicroscopy, and determinations of BCVA. Specifically, AEs were collected after the initial study drug instillation on day 0 through the end of the study at day 2. The assessments of ocular signs and BCVA were conducted at screening and prior to exiting the study at day 2.

### Statistics

All eligible patients who received study drugs and completed the ODS and the patient preference question on days 1 and 2 were included in the per-protocol (PP) population. All patients who had at least one instillation of study drug were included in the safety population.

The primary efficacy endpoint was the percentage of patients with a stated preference for either study medication, as assessed with the patient preference question. The difference in the percentage of patients (PP population) who had a preference for either brinzolamide/timolol or dorzolamide/timolol was determined using a one-sample Chi-square test.

The secondary efficacy endpoint was the difference in the mean ODS score for the two study medications. The difference in the mean ODS score reported for brinzolamide/timolol and dorzolamide/timolol (PP population) was determined using a Chi-square test.

Safety was evaluated by reviewing reported AEs and changes in ocular signs and BCVA assessments from day 0 to day 2 (safety population).

Results
=======

Patient characteristics and disposition
---------------------------------------

A total of 120 patients were enrolled at six investigational centers in South America (three in Argentina, one in Brazil, and two in Chile). All enrolled patients (n = 120) were included in the safety population and 115 were included in the PP population.

Patient demographics and baseline characteristics were analyzed for the PP population. The demographic and baseline characteristics of patients in each treatment group were similar ([Table 1](#t1-opth-7-357){ref-type="table"}). Nearly two-thirds of enrolled patients (64.3%) were women, and most (93.9%) had primary open-angle glaucoma.

### Patient preference

On day 2, of the 115 patients in the PP population, 112 expressed a preference for one study drug, while three patients expressed no preference. Of the 112 patients with a stated preference, a significantly greater percentage preferred brinzolamide/timolol compared with dorzolamide/timolol (67.0% versus 30.4%; *P* \< 0.001) ([Figure 1](#f1-opth-7-357){ref-type="fig"}).

### Ocular discomfort

On day 1, no significant differences were observed between treatment groups in the ODS score, expressed as mean (standard deviation \[SD\]), after study-drug instillation (brinzolamide/timolol = 2.4 \[2.6\]; dorzolamide/timolol = 3.3 \[2.9\]; *P* = 0.0770). However, on day 2, patients who received brinzolamide/timolol had a significantly lower mean (SD) ODS score after drop instillation than did patients who received dorzolamide/timolol (1.9 \[2.3\] versus 3.7 \[2.8\]; *P* = 0.0003). Further, when data from both days were combined, the mean (SD) ODS score for all patients after instillation of brinzolamide/timolol was significantly lower than that for all patients after instillation of dorzolamide/timolol (2.1 \[2.5\] versus 3.5 \[2.9\]; *P* = 0.00014) ([Figure 2](#f2-opth-7-357){ref-type="fig"}).

### Safety

No serious AEs occurred. On day 0, three patients had one AE each, including dry throat (mild intensity), headache (mild intensity), and bitter taste (mild intensity). Day 0 events could not be assessed for relatedness to a specific study treatment because patients received one drop each of both study drugs. On day 1, five patients receiving brinzolamide/timolol reported five nonserious AEs: flu (n = 1), bitter taste (n = 2), and headache (n = 2). Four of these events, bitter taste (two events) and headache (two events), were considered by the investigators to be related to brinzolamide/timolol. All day 1 AEs were mild in intensity, with the exception of bitter taste of moderate intensity reported by one patient. No AEs were reported at day 2. All AEs resolved without additional treatment, and none resulted in patient discontinuation from the study. No clinically relevant changes from baseline were observed in BCVA or slit-lamp examinations of ocular signs.

Discussion
==========

Fixed combinations of different classes of IOP-lowering agents in the same bottle offer advantages over the use of the same individual drugs in separate bottles, such as a simplified dosing regimen and the elimination of the washout effect that occurs when multiple drugs are instilled without an adequate waiting period between instillations.[@b9-opth-7-357],[@b10-opth-7-357] Patient adherence to therapy may be influenced not only by efficacy and dosing regimen, but also by drop comfort upon instillation and overall tolerability.[@b8-opth-7-357] Ocular comfort upon instillation, in particular, is a critical aspect of the overall tolerability of any topical ocular medication, and low tolerability has been identified as a barrier to treatment adherence.[@b11-opth-7-357]

In the present study, ocular discomfort, as quantified by the mean ODS score, was significantly lower after instillation of brinzolamide/timolol than after instillation of dorzolamide/timolol (*P* = 0.00014). This observation is consistent with a previous study that used the same scale[@b12-opth-7-357] and also with other studies that used different scales to evaluate the comfort of the same two fixed-combination medications.[@b13-opth-7-357],[@b14-opth-7-357] Further, in a recent open-label, multicenter, observational study of more than 14,000 patients in Germany,[@b15-opth-7-357] nearly two-thirds more of the patients who transitioned from dorzolamide/timolol to brinzolamide/timolol (n = 2937) rated the latter drug as the more tolerable treatment (brinzolamide/timolol: 88.9%; dorzolamide/timolol: 28.9%). Patients in this study also preferred brinzolamide/timolol to previous therapy by a ratio of almost 9:1. A possible reason for the superior ocular comfort of brinzolamide/timolol relative to dorzolamide/timolol is that the brinzolamide/timolol formulation has a pH that is closer to the physiological pH of human eyes than that of the dorzolamide/timolol formulation.[@b16-opth-7-357],[@b17-opth-7-357] In addition, the brinzolamide/timolol product is formulated without additional buffers, while the dorzolamide/timolol product is buffered using sodium citrate,[@b16-opth-7-357],[@b17-opth-7-357] which could irritate the ocular surface upon drop instillation.

A greater percentage of patients in the present study preferred brinzolamide/timolol to dorzolamide/timolol (67% versus 30%). These results were consistent with a previously reported direct-comparison study conducted in the United States, in which the majority of patients expressing a preference preferred brinzolamide/timolol to dorzolamide/timolol (79% versus 21%; *P* \< 0.0001).[@b12-opth-7-357] When the observed patient preference for brinzolamide/timolol relative to dorzolamide/timolol is considered in combination with the observed lower ODS score associated with brinzolamide/timolol, the study results support the relationship that has been proposed in the literature between drop comfort and patient preference.[@b18-opth-7-357]

A positive correlation between patient preference and likelihood of adherence to therapy was suggested in a study of 447 glaucoma patients who transitioned from dorzolamide to brinzolamide.[@b19-opth-7-357] Further, a recent study found that patients with open-angle glaucoma who adhered to their treatment (as measured using an electronic dosing aid) experienced diminished progression or worsening of visual field function.[@b20-opth-7-357] Thus, high therapeutic adherence rates may be associated with better clinical outcomes in glaucoma. If this is true, the results of this study suggest that patients who are treated with brinzolamide/timolol have the potential for good treatment adherence.

Four AEs were assessed as related to brinzolamide/timolol, both of which occurred on day 1: bitter taste (two reports: one mild and one moderate in intensity) and headache (two reports: both mild). In a previous clinical study wherein patients received brinzolamide/timolol or dorzolamide/timolol twice daily for 12 months, the incidence of dysgeusia (bad taste) was low and was reported at a similar frequency in both treatment groups (2.8%--3.2%).[@b7-opth-7-357] Dysgeusia is a known adverse effect of carbonic anhydrase inhibitors.[@b21-opth-7-357] Overall, based on AEs and changes in ocular signs and visual acuity, no safety issues or trends were observed during the present study.

These study results were limited due to a short-term exposure to each study drug. Long-term exposure to either drug may influence patient perceptions of comfort. Evaluation of the effects on ocular signs, as assessed by biomicroscopy, was limited by the brief exposure to study drug and short study duration. There was no washout period before study initiation, and patients with previous exposure to the individual component agents of the study drugs were not excluded. While these limitations had the potential to introduce bias, this effect was minimized by the randomized crossover study design that implemented within-patient comparisons.

Conclusion
==========

Patients in this study experienced less discomfort upon instillation of brinzolamide/timolol compared with dorzolamide/timolol, and more patients expressed a preference for brinzolamide/timolol than for dorzolamide/timolol. Both brinzolamide/timolol and dorzolamide/timolol were generally safe and well tolerated.
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![Patient preference for study medication.\
**Notes:** On day 2, of the 115 patients in the per-protocol population, three expressed no preference for one study drug over the other; these patients are not included in the figure. \*Significant difference between treatments; *P* \< 0.001 (n = 112; per-protocol population). *P*-value was calculated from a Chi-square test.](opth-7-357Fig1){#f1-opth-7-357}

![Mean ocular discomfort scores with standard error of the mean error bars after instillation of brinzolamide/timolol or dorzolamide/timolol.\
**Notes:** Data from day 1 and day 2 were combined; lower scores indicate less discomfort. Data are mean ocular discomfort scores ± standard error of the mean. \*Significant difference between treatments; *P* = 0.00014 (n = 115; per-protocol population). *P*-value was calculated from a Chi-square test.](opth-7-357Fig2){#f2-opth-7-357}

###### 

Demographic and baseline characteristics

                                 Brinzolamide/timolol (n = 58)   Dorzolamide/timolol (n = 57)   *P*-value
  ------------------------------ ------------------------------- ------------------------------ ---------------------------------------------------
  Age, years                                                                                    0.5818[a](#tfn2-opth-7-357){ref-type="table-fn"}
   Mean (standard deviation)     64.2 (13.6)                     65.7 (15.7)                    
   Range (minimum, maximum)      (22, 85)                        (19, 89)                       
  Sex, n (%)                                                                                    0.2159[b](#tfn3-opth-7-357){ref-type="table-fn"}
   Men                           17 (29.3)                       24 (42.1)                      
   Women                         41 (70.7)                       33 (57.9)                      
  Race, n (%)                                                                                   \>0.999[c](#tfn4-opth-7-357){ref-type="table-fn"}
   White                         46 (79.3)                       46 (80.7)                      
   Hispanic                      10 (17.2)                       10 (17.5)                      
   Black                         1 (1.7)                         1 (1.8)                        
   Asian                         1 (1.7)                         0 (0.0)                        
  Glaucoma diagnosis, n (%)                                                                     0.7167[c](#tfn4-opth-7-357){ref-type="table-fn"}
   Ocular hypertension           3 (5.2)                         4 (7.0)                        
   Primary open-angle glaucoma   55 (94.8)                       53 (93.0)                      
  Intraocular pressure, mmHg                                                                    0.3706[a](#tfn2-opth-7-357){ref-type="table-fn"}
   Mean (standard deviation)     15.9 (3.3)                      15.6 (2.5)                     
   Range (minimum, maximum)      (9--27)                         (8--22)                        

**Notes:** Treatment groups were based on the randomization assignment for day 1, or the per-protocol population.

*P*-value calculated from a *t*-test;

*P*-value calculated from a Chi-square test;

*P*-value calculated from a Fisher's exact test.
